Adiponectin-resistin (AR) index (fasting serum total adiponectin and resistin levels) and insulin resistance-AR (IRAR) index (integration of the AR index into an existing insulin resistance index) have been used to screen individuals with elevated risk of potential progress of T2DM and metabolic syndrome before [208], recent study found that both of them applies on cardiovascular risk in diabetic patients as well [209]. Here, ADIPOQ is linked to metabolic syndrome.